<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-21T02:37:42Z</responseDate><request verb="GetRecord" identifier="oai:macsphere.mcmaster.ca:11375/32600" metadataPrefix="dim">https://prod-ms-be.lib.mcmaster.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:macsphere.mcmaster.ca:11375/32600</identifier><datestamp>2026-09-24T05:09:48Z</datestamp><setSpec>com_11375_271</setSpec><setSpec>col_11375_272</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor">Trigatti, Bernardo</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author">Yoo, Jeong-Ah</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="department" lang="en_US">Biochemistry and Biomedical Sciences</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2025-10-28T12:54:17Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2025-10-28T12:54:17Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2025-11</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/11375/32600</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://doi.org/10.71548/15627</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">Doxorubicin (DOX) is one of the most commonly used chemotherapeutic agents in human &#xd;
cancer therapy, but the clinical use of DOX is restricted by its dose-dependent cardiac &#xd;
toxicity. Therapies based on high-density lipoprotein (HDL) or its major protein, &#xd;
apolipoprotein (Apo) A1 can specifically protect the heart against doxorubicin (DOX)-&#xd;
induced apoptosis and atrophy without affecting DOX anti-tumor activity, as demonstrated &#xd;
in this thesis. In vitro, HDL, but not ApoA1, decreased apoptosis and atrophy in neonatal &#xd;
cardiomyocytes but did not provide protection to breast tumor cells against DOX &#xd;
cytotoxicity. Both ApoA1 and HDL were cardioprotective against DOX cardiomyocyte &#xd;
apoptosis and atrophy in mice bearing tumors, while still providing tumor suppression. &#xd;
Mechanistically, we demonstrated that ApoA1-induced cardioprotection required hepatic &#xd;
expression of the HDL receptor, scavenger receptor class B type I (SR-B1), but not &#xd;
expression of SR-B1 in cardiomyocytes. These results reveal that the liver, but not the &#xd;
cardiomyocyte, is a key site mediating the protective effect of ApoA1 against the &#xd;
cardiotoxicity of chemotherapy. These findings provide new evidence for the specific role &#xd;
of HDL-SR-B1 interactions in cardiomyocytes and liver and set the foundation for &#xd;
strategies to reduce cardiotoxicity during cancer treatment while maintaining its anti-cancer &#xd;
effect.</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degreetype" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degree" lang="en_US">Doctor of Philosophy (PhD)</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso" lang="en_US">en</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">INVESTIGATING APOA1 AND HDL-MEDIATED PROTECTION AGAINST  DOXORUBICIN-INDUCED CARDIOTOXICITY</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="others" element="access-status">embargo</dim:field>
</dim:dim></metadata></record></GetRecord></OAI-PMH>